跳至主要内容
临床试验/CTRI/2018/02/012101
CTRI/2018/02/012101已完成3 期

A Randomized, Comparative, Open Clinical Trial for Evaluating the Efficacy of JLN/PP/108 Suspension in the Management of Functional Dyspepsia and Reflux Oesophagitis.

Dabur India Limited0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Inclusion Criteria:-Functional (Non â??ulcer)Dyspepsia(NUD)
  • 1 Subjects with 24% of dyspepsia as per the Hong Kong Index of Dyspepsia
  • 2 Subjects with normal upper gastrointestinal endoscopy, absence of any clinical, or ultrasonographic evidence of organic disease that would account for the symptoms.
  • 3 In the event of patient undergoing treatment for dyspepsia, washout period of 1 week was mandatory.
  • 4 Willingness to sign informed consent and to come for regular follow- up examinations as & when required.
  • Inclusion Criteria:- Gastrointestinal Esophageal Reflux disorder(GERD)
  • 5 Subjects suffering from Reflux oesophagitis.
  • 6 Subjects complaining for more than 25 percent of the time like heartburn, regurgitation, for at least 1 month.
  • 7 Subjects with Grade o and Grade I of GERD symptoms.
  • 8 Subjects with gastrointestinal endoscopy positive and negative evidence.
  • 9 Willingness to sign informed consent and to come for regular follow- up examinations as & when required.

排除标准

  • Exclusion Criteria:-Functional (Non â??ulcer)Dyspepsia(NUD
  • 1 Subjects suffering from peptic and duodenal ulcers.
  • 2 Family history of peptic ulcer disease or gastric malignancy.
  • 3 Subjects suffering from Reflux oesophagitis.
  • 4 Subjects with chronic NSAID and steroids ( > 1 month) use with or without evidence of an ulcer
  • 5 Uncooperative Subjects or subjects not willing to sign Informed Consent or giving consent for study required procedure like endoscopy.
  • 6 Subjects with clinically diagnosed serious medical illness (Diabetes, SLE, Rheumatoid Arthritis, Rheumatic Arthritis, Psoriatic Arthritis), surgical illness where compliance is difficult.
  • 7 Subjects on any other medication for the treatment of acidity other than specified in the study.
  • 8 Subjects not willing to follow up for the study visits.
  • 9 Subjects with age range below 16 years and above 65 years; dyspepsia persisting for less than 1 month before endoscopy;
  • 10 Clinical evidence of irritable bowel syndrome; prior gastric surgery or proven peptic ulceration in the past;
  • 11 Subjects with history of upper G.I. bleeding;
  • 12 Subjects with overwhelming physical or mental disease (this includes subjects with carcinoma, pancreatitis, gall bladder disease, acute and chronic liver disease, bowel obstruction, chronic diarrhea and major psychosis);
  • Exclusion Criteria:- Gastrointestinal Esophageal Reflux disorder(GERD)
  • 13 Family history of peptic ulcer disease or gastric malignancy.
  • 14 Subjects not giving consent for study required procedure like endoscopy.
  • 15 Subjects with chronic NSAID use ( > 1month) with or without evidence of an ulcer.
  • 16 Subjects not willing to sign Informed Consent.
  • 17 Subjects with clinically diagnosed serious medical illness (Diabetes, SLE, Rheumatoid Arthritis, Rheumatic Arthritis, Psoriatic Arthritis), surgical illness where compliance is difficult.
  • 18 Subjects on any other medication for the treatment of acidity other than specified in the study.
  • 19 Subjects not willing to follow up for the study visits.
  • 20 Patients meeting the above inclusion and exclusion criteria were made fully aware of the type of treatment given to them and then informed consent were taken.

研究者

相似试验